These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model. Schultes BC; Zhang C; Xue LY; Noujaim AA; Madiyalakan R Hybridoma; 1999 Feb; 18(1):47-55. PubMed ID: 10211788 [TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer: designing effective vaccines and specific diagnostic tools. Spinosa JP; Kanduc D Immunotherapy; 2014; 6(1):35-41. PubMed ID: 24341882 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines--a preliminary report. Reinartz S; Boerner H; Koehler S; Von Ruecker A; Schlebusch H; Wagner U Hybridoma; 1999 Feb; 18(1):41-5. PubMed ID: 10211787 [TBL] [Abstract][Full Text] [Related]
33. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
34. Dendritic cell-based vaccines in patients with hematological malignancies. Brugger W; Schneider A; Schammann T; Dill P; Grünebach F; Bühring HJ; Kanz L; Brossart P Ann N Y Acad Sci; 2001 Jun; 938():359-62; discussion 362-3. PubMed ID: 11458523 [TBL] [Abstract][Full Text] [Related]
35. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Chiriva-Internati M; Mirandola L; Kast WM; Jenkins MR; Cobos E; Cannon MJ Int Rev Immunol; 2011; 30(2-3):71-86. PubMed ID: 21557635 [TBL] [Abstract][Full Text] [Related]
36. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730 [TBL] [Abstract][Full Text] [Related]
37. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer. Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352 [TBL] [Abstract][Full Text] [Related]
38. Dendritic cell immunotherapy. Sabado RL; Bhardwaj N Ann N Y Acad Sci; 2013 May; 1284():31-45. PubMed ID: 23651191 [TBL] [Abstract][Full Text] [Related]